Phase 1b/2 Single‐arm Trial Evaluating the Combination of Lapatinib, Everolimus, and Capecitabine for the Treatment of Patients With HER2‐positive Metastatic Breast Cancer With CNS Progression After Trastuzumab. Here, ERBB2 is linked to breast carcinoma.